Purpura thrombocytopenicM31.1

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Polyätiological, microangiopathic, mostly small spotted purpura (petechiae) caused by thrombocytopenia of varying aetiology and severity.

EtiopathogenesisThis section has been translated automatically.

The causes of thrombocytopenia include:

  • educational disorders:
    • Diminished megakaryocytopoiesis:
      • Congenital
      • Acquired: E.g. by drugs, radiotherapy, chemicals, viruses, bacterial infections.
      • Displacement: E.g. by bone marrow carcinosis, leukemia, malignant lymphomas (e.g. plasmocytoma), osteomyelofibrosis.
    • Ineffective thrombocytopoiesis: e.g. Wiskott-Aldrich syndrome.
  • Increased degradation or consumption:
    • Immunological:
      • Primary autoantibody formation: e.g. idiopathic thrombocytopenic purpura.
      • Secondary autoantibody production: e.g. drugs, collagenosis, immune complex diseases, antiphospholipid antibody syndrome).
    • Non-immunological:
      • E.g. disseminated intravascular coagulation.
  • distribution disorders:
    • E.g. platelet pooling in the spleen for splenomegaly.

Clinical featuresThis section has been translated automatically.

Hemorrhages, ecchymoses, suggestions- Capillary damage is also common.

TherapyThis section has been translated automatically.

  • Varies depending on the triggering cause.
  • Avoid a triggering drug. Depending on the clinic and platelet count, systemic glucocorticoids are indicated, e.g. prednisone (e.g. Decortin) initial 100 mg/day, gradual reduction according to clinic.
  • The treatment of thrombocytopenia is a treatment to be carried out under internal control.

Note(s)This section has been translated automatically.

The thrombocytopenic purpura is not to be confused with the Moschcowitz syndrome, the thrombotic-thrombocytopenic purpura.

Authors

Last updated on: 29.10.2020